(Bloomberg) -- New cancer drugs from Pfizer Inc. and
Genentech Inc., tested together for the first time, raised each
medicine's tumor fighting power, researchers reported this week.
The therapy is heralding a new era in fighting cancer by
combining drugs that interfere with the biochemical pathways that
fuel cancer. By using Sutent, made by New York-based Pfizer, and
Avastin, from South San Francisco-based Genentech, researchers
say they achieved a 71 percent reduction in difficult-to-treat
kidney tumors in a small study.
Read more at Bloomberg Exclusive News
Genentech Inc., tested together for the first time, raised each
medicine's tumor fighting power, researchers reported this week.
The therapy is heralding a new era in fighting cancer by
combining drugs that interfere with the biochemical pathways that
fuel cancer. By using Sutent, made by New York-based Pfizer, and
Avastin, from South San Francisco-based Genentech, researchers
say they achieved a 71 percent reduction in difficult-to-treat
kidney tumors in a small study.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment